A Combination of Budesonide and the SH-Metabolite I of Erdosteine Acts Synergistically in Reducing Chemiluminescence during Human Neutrophil Respiratory Burst
- 1 June 2005
- journal article
- Published by S. Karger AG in Pharmacology
- Vol. 74 (3), 127-134
- https://doi.org/10.1159/000084295
Abstract
Activated neutrophils can release superoxide anion and nitric oxide (NO), which subsequently combine with each other to yield peroxynitrite anions, powerful and harmful oxidants that preferentially mediate the oxidation of the thiol groups in proteins and non-protein molecules. These oxidants play a direct role in the inflammatory process in chronic obstructive pulmonary disease and asthma by increasing the number of neutrophils and macrophages that induce a self-sustaining phlogogenic loop. Budesonide (BUD) and erdosteine (a muco-active drug which, after metabolization, produces an active metabolite (Met I) with a sulfhydryl group) are both active in reducing the release of superoxide anion, NO and peroxynitrite, and can be administered to patients with respiratory diseases. The aim of this study was to investigate the possible synergistic in vitro effect of BUD and Met I on chemiluminescence generation during fMLP-stimulated respiratory bursts of human neutrophils with the NO donor L-arginine, added to the incubating medium. The investigated BUD concentrations ranged from 6 x 10(-8) to 1 x 10(-6) mol/l in logarithmic scale and a significant and progressive reduction in luminol-amplified chemiluminescence (LACL) was observed at concentrations ranging from 2.5 x 10(-7) to 1 x 10(-6) mol/l. The investigated concentrations of Met I varied from 0.62 to 10 microg/ml. No significant changes were observed at 0.62, 1.25, and 2.5 microg/ml, but a significant decrease in LACL was observed at 5 and 10 microg/ml. When the two drugs were combined, there was a greater significant decrease in LACL versus the single drugs with the combinations of BUD 1 x 10(-6) mol/l plus Met I 10 microg/ml, BUD 5 x 10(-7) mol/l plus Met I 5 microg/ml, BUD 2.5 x 10(-7) mol/l plus Met I 2.5 microg/ml, and BUD 1.25 x 10(-7) mol/l plus Met I 1.25 microg/ml. A further interesting finding was that the combination of BUD 2.5 x 10(-7) mol/l plus Met I 2.5 microg/ml and BUD 1.25 x 10(-7) mol/l plus Met I 1.25 microg/ml significantly decreased LACL, whereas the single concentrations had no significant effect, thus indicating the possibility of extending the duration of the effect. Our findings indicate a synergistic antioxidant effect when BUD and Met I are given together, which is of interest for counteracting the airway phlogosis involved in many respiratory diseases.Keywords
This publication has 56 references indexed in Scilit:
- Budesonide Reduces Superoxide and Peroxynitrite Anion Chemiluminescence during Human Neutrophil BurstsPharmacology, 2005
- Inhibitory Effects of Metabolite I of Erdosteine on the Generation of Nitric Oxide and Peroxynitrite Chemiluminescence by Human NeutrophilsPharmacology, 2004
- Imbalance between levels of nitrogen oxides and peroxynitrite inhibitory activity in chronic obstructive pulmonary diseaseThorax, 2003
- Nitric oxide regulates the chemiluminescence from stimulated human neutrophilsAPMIS, 1995
- The production of cytokines by polymorphonuclear neutrophilsImmunology Today, 1995
- Enhancement of reactive oxygen species formation in stable and unstable asthmatic patientsEuropean Respiratory Journal, 1994
- Kinetics of nitric oxide and hydrogen peroxide production and formation of peroxynitrite during the respiratory burst of human neutrophilsFEBS Letters, 1994
- Glucocorticoids inhibit the induction of nitric oxide synthase in macrophagesBiochemical and Biophysical Research Communications, 1990
- Formation and release of nitric oxide from human neutrophils and HL‐60 cells induced by a chemotactic peptide, platelet activating factor and leukotriene B4FEBS Letters, 1989
- Active Oxygen Species and the Functions of Phagocytic LeukocytesAnnual Review of Biochemistry, 1980